These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 11134280)

  • 1. Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression.
    Sabbe R; Picchio GR; Pastore C; Chaloin O; Hartley O; Offord R; Mosier DE
    J Virol; 2001 Jan; 75(2):661-71. PubMed ID: 11134280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.
    Mosier DE; Picchio GR; Gulizia RJ; Sabbe R; Poignard P; Picard L; Offord RE; Thompson DA; Wilken J
    J Virol; 1999 May; 73(5):3544-50. PubMed ID: 10196243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.
    Kawamura T; Bruse SE; Abraha A; Sugaya M; Hartley O; Offord RE; Arts EJ; Zimmerman PA; Blauvelt A
    J Virol; 2004 Jul; 78(14):7602-9. PubMed ID: 15220435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.
    Pastore C; Picchio GR; Galimi F; Fish R; Hartley O; Offord RE; Mosier DE
    Antimicrob Agents Chemother; 2003 Feb; 47(2):509-17. PubMed ID: 12543651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity.
    Mack M; Luckow B; Nelson PJ; Cihak J; Simmons G; Clapham PR; Signoret N; Marsh M; Stangassinger M; Borlat F; Wells TN; Schlöndorff D; Proudfoot AE
    J Exp Med; 1998 Apr; 187(8):1215-24. PubMed ID: 9547333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocytosis and recycling of the HIV coreceptor CCR5.
    Signoret N; Pelchen-Matthews A; Mack M; Proudfoot AE; Marsh M
    J Cell Biol; 2000 Dec; 151(6):1281-94. PubMed ID: 11121442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.
    Marozsan AJ; Torre VS; Johnson M; Ball SC; Cross JV; Templeton DJ; Quiñones-Mateu ME; Offord RE; Arts EJ
    J Virol; 2001 Sep; 75(18):8624-38. PubMed ID: 11507208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.
    Hartley O; Gaertner H; Wilken J; Thompson D; Fish R; Ramos A; Pastore C; Dufour B; Cerini F; Melotti A; Heveker N; Picard L; Alizon M; Mosier D; Kent S; Offord R
    Proc Natl Acad Sci U S A; 2004 Nov; 101(47):16460-5. PubMed ID: 15545608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of RANTES- and aminooxypentane-RANTES-triggered desensitization signals reveals differences in recruitment of the G protein-coupled receptor complex.
    Vila-Coro AJ; Mellado M; Martín de Ana A; Martínez-A C; Rodríguez-Frade JM
    J Immunol; 1999 Sep; 163(6):3037-44. PubMed ID: 10477567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
    Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
    J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors.
    Proudfoot AE; Buser R; Borlat F; Alouani S; Soler D; Offord RE; Schröder JM; Power CA; Wells TN
    J Biol Chem; 1999 Nov; 274(45):32478-85. PubMed ID: 10542293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking.
    Kiss DL; Longden J; Fechner GA; Avery VM
    Cell Mol Biol Lett; 2009; 14(4):537-47. PubMed ID: 19448977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus.
    Oppermann M; Mack M; Proudfoot AE; Olbrich H
    J Biol Chem; 1999 Mar; 274(13):8875-85. PubMed ID: 10085131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5.
    Lin YL; Mettling C; Portalès P; Rouzier R; Clot J; Reynes J; Corbeau P
    AIDS; 2008 Jan; 22(3):430-2. PubMed ID: 18195571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene polymorphisms in CCR5, CCR2, SDF1 and RANTES among Chinese Han population with HIV-1 infection.
    Li H; Liu TJ; Hong ZH
    Infect Genet Evol; 2014 Jun; 24():99-104. PubMed ID: 24650919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The allergy-associated chemokine receptors CCR3 and CCR5 can be inactivated by the modified chemokine NNY-CCL11.
    Manns J; Rieder S; Escher S; Eilers B; Forssmann WG; Elsner J; Forssmann U
    Allergy; 2007 Jan; 62(1):17-24. PubMed ID: 17156337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection.
    Yun JJ; Whiting D; Fischbein MP; Banerji A; Irie Y; Stein D; Fishbein MC; Proudfoot AE; Laks H; Berliner JA; Ardehali A
    Circulation; 2004 Feb; 109(7):932-7. PubMed ID: 14757698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferation.
    Rusconi S; La Seta-Catamancio S; Kurtagic S; Galazzi M; Arienti D; Trabattoni D; Wilken J; Thompson DA; Offord RE; Galli M; Clerici M
    AIDS Res Hum Retroviruses; 1999 Jul; 15(10):861-7. PubMed ID: 10408722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of human immunodeficiency virus-1 (HIV-1) by beta-chemokine analogues in mononuclear cells from HIV-1-infected patients with active tuberculosis.
    Toossi Z; Mayanja-Kizza H; Baseke J; Peters P; Wu M; Abraha A; Aung H; Okwera A; Hirsch C; Arts E
    Clin Exp Immunol; 2005 Nov; 142(2):327-32. PubMed ID: 16232220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry.
    Jin J; Colin P; Staropoli I; Lima-Fernandes E; Ferret C; Demir A; Rogée S; Hartley O; Randriamampita C; Scott MG; Marullo S; Sauvonnet N; Arenzana-Seisdedos F; Lagane B; Brelot A
    J Biol Chem; 2014 Jul; 289(27):19042-52. PubMed ID: 24855645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.